Nepanizil (Donepezil Hydrochloride)

Donepezil Hydrochloride, the active ingredient in Nepanizil, is an acetylcholinesterase inhibitor presented as a tablet for oral use. It treats mild to moderate Alzheimer’s disease in adults.

GNH USA supplies Nepanizil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Donepezil is used in the management of Alzheimer’s disease, a neurodegenerative disorder affecting cognition and function.

- Mild to moderate Alzheimer’s disease: improves cognitive function and daily living activities. - Alzheimer’s disease-related behavioral symptoms: helps reduce agitation and confusion. - Cognitive decline in early Alzheimer’s: provides symptomatic benefit in memory and attention.

Donepezil may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: increased bowel movements. - Insomnia: difficulty falling or staying asleep. - Muscle cramps: occasional skeletal muscle discomfort. - Fatigue: feeling of tiredness or low energy. - Loss of appetite: reduced desire to eat.

Serious or Rare Side Effects: - Bradycardia: significant slowing of heart rate. - Syncope: fainting episodes. - Severe vomiting: persistent, forceful emesis. - Hepatic injury: abnormal liver function tests. - Seizures: rare convulsive events. - Allergic reactions: rash, swelling, or anaphylaxis.

When prescribing Donepezil, clinicians should consider several safety aspects.

- Dose adjustment: evaluate renal or hepatic impairment before initiating therapy. - Cardiac monitoring: use caution in patients with conduction disorders or bradyarrhythmias. - Discontinuation: avoid abrupt cessation as it may worsen cognition. - Gastrointestinal risk: use carefully in patients with peptic ulcer disease. - Pregnancy safety: unknown; prescribe only if benefits outweigh potential risks. - Store at ambient temperature: keep in the original container, protect from moisture.

Donepezil can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase plasma concentrations. - Anticholinergic drugs: may diminish therapeutic effect. - Other acetylcholinesterase inhibitors: risk of cholinergic excess.

Moderate Interactions (Monitor Closely): - NSAIDs: may raise risk of gastrointestinal bleeding. - Beta‑blockers: can exacerbate bradycardia. - Antidepressants (e.g., SSRIs): monitor for additive serotonergic effects.